Key result
Leadless pacemaker safely resolves symptoms in a heart transplant recipient over 7 months.
Why the study?
A significant proportion of heart transplant recipients require permanent pacemaker implantation due to sinus node dysfunction or AV block, but data on leadless pacemaker use in this population are limited.
Case Report (n=1)
No
Describes the first use of the Aveir VR leadless pacemaker in a heart transplant recipient in Poland.
Answers are grounded in this paper and cite their sources.
May support leadless pacing feasibility post-transplant; leaves open need for prospective data before wider use.
Orthotopic heart transplant (OHT) is a life-saving procedure, most commonly performed for ischemic and non-ischemic cardiomyopathy [1].Approximately 4.5% to 20% of heart transplant recipients require permanent pacemaker implantation, typically due to sinus node dysfunction or atrioventricular (AV) block [2, 3].Traditional transvenous pacemakers are
No takes yet. Share an insight, caveat, or question.
Lewandowski et al. (2025) conducted a case report in Sinus node dysfunction and atrioventricular block in a heart transplant recipient (n=1). Abbott Aveir VR single-chamber leadless pacemaker was evaluated on Safety, efficacy, and electrical parameters of the leadless pacemaker. Implantation of a single-chamber leadless pacemaker in a heart transplant recipient was safe and effective, resulting in stable electrical parameters and resolution of symptoms over a 7-month follow-up.
Synapse has enriched 10 related papers. Consider them for comparative context: